Compounded semaglutide does not have one universal price.
The useful cost is the amount due for a specific prescription and plan, after identifying the billing interval, prepayment requirement, medication status, consultation or membership charges, shipping, supplies, and any exclusions. A low monthly equivalent can require a larger payment today. Product availability, clinician decisions, and plan terms can change. A licensed clinician’s evaluation and prescription remain necessary.[3] [4]
Start with the amount due, not a headline number
“How much does compounded semaglutide cost?” can describe several different transactions. One program may quote a month-to-month amount. Another may convert a prepaid three-, six-, or twelve-month purchase into a lower monthly equivalent. A plan may bundle consultation, prescription, medication, and shipping, while another can charge some of those items separately. A 28-day cycle is also not identical to a calendar month. Before comparing any two offers, ask what is charged now, what recurs, and what is included in writing.
Henry Meds illustrates why billing terms matter. Its legal program page lists injectable compounded semaglutide at $297 monthly or $2,364 for a twelve-month paid-in-full option. Its active landing page advertises $197 per month only with twelve months paid upfront—the same annual equivalent, not a $197 monthly bill. Confirm the prescribed plan, included supplies, shipment schedule, and cancellation obligations; these advertised terms are not a guaranteed individual quote.[5] [6]
For branded context, NovoCare lists Wegovy injection pens at $349 per box of four pens for the listed 0.25–2.4 mg strengths. Its $199 introductory offer covers two monthly fills of 0.25 mg and 0.5 mg for eligible new patients through December 31, 2026; it is not the ongoing price. Other formulations have different prices. Eligibility and offer restrictions apply, and terms may change. This medication offer is not a complete telehealth-care package or evidence that a compounded preparation is interchangeable.[7]
Current published Luma terms
| Billing choice | Published amount checked September 17, 2026 | What the stated price includes or requires |
|---|---|---|
| Commercial disclosure: Luma Health sells compounded semaglutide and has a commercial interest in readers choosing it. This is Luma’s published pricing, not an independent market comparison. | ||
| Month to month | $120 per month[1] | Billed monthly with no minimum term. Luma says plans include provider consultation, prescription, medication, and shipping. |
| 3-month plan | $240 total; $80 per-month equivalent[1] | The $240 total is paid in full if prescribed. The $80 figure is an equivalent, not the initial charge. |
| 6-month plan | $470 total; about $78 per-month equivalent[1] | The $470 total is paid in full if prescribed. The published page does not make this a monthly-billed plan. |
| 12-month plan | No numerical semaglutide price published[1] | Luma says to ask a provider during consultation for current 12-month pricing. This article does not infer a price. |
Compare cash due today as well as the equivalent monthly rate. A prepaid discount changes both commitment and cash flow. Check the controlling page again before payment because published plan details can change.[1]
These figures are not a recommendation, a guarantee of a prescription, or a claim that Luma is the lowest-cost option. They also do not establish what another program charges, whether a person is eligible, or whether a particular preparation is appropriate. A person considering any program can ask for the exact product, total first charge, recurring charge, term, renewal and cancellation terms, laboratory or supply charges where applicable, and the dispensing pharmacy’s identity before deciding.
Use the same worksheet for every quote
A comparable quote answers six questions in the same order: What exact finished product or compounded preparation is being offered? What is charged today? Is the billing period a calendar month, 28 days, or a prepaid term? Which services are included? What can be charged separately? What happens at renewal or cancellation? Record the answer from the provider’s own current page or written terms, along with the date checked. If a plan has a lower equivalent rate because several months are prepaid, list both the total due and the equivalent rate. If the product category, plan term, or included services differ, the figures are not like-for-like prices.
Insurance can create a separate calculation. A person using insurance should confirm the specific product, deductible, prior-authorization requirement, network pharmacy, copay or coinsurance, and manufacturer-program restrictions with the relevant plan and program administrator. A self-pay page cannot predict an insurance benefit, and an insurance estimate cannot promise a cash price. These checks are practical ways to identify the expected cost; they do not determine whether a clinician will prescribe a product.
Cost context: an FDA-approved product and a compounded preparation are different categories
Wegovy is an FDA-approved finished semaglutide drug product for its labeled uses. Compounded semaglutide is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. The presence of “semaglutide” in two descriptions does not make the finished products interchangeable, equivalent, or shown to have the same outcomes. This guide therefore does not apply Wegovy labeling or clinical-study results to a compounded preparation.[3] [4]
FDA says compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug. The appropriate product, if any, is a clinician-specific decision. A price comparison cannot establish clinical suitability, resolve contraindications, replace a review of other medicines or pregnancy plans, or authorize a switch between products. For a brand-focused cost discussion, see the Wegovy cost guide; for a separate explanation of product distinctions, see compounded semaglutide versus Wegovy.
FDA policy affects how cost claims should be read
FDA’s April 1, 2026 policy update says semaglutide does not currently appear on FDA’s drug shortage list or the 503B bulks list. Under section 503A, a compounded drug product must be for an individual patient based on a prescription, and the compounder generally may not compound, regularly or in inordinate amounts, an essentially-copy commercial product. FDA describes a documented prescriber determination of a significant difference for an identified patient as the relevant exception to its “essentially a copy” description. The details are legal and factual conditions, not a promise that a routine offer is lawful or available in every state.[2]
For that reason, a price page alone cannot verify that a compounded preparation is appropriate, available to a given person, or compliant with every applicable requirement. Do not treat a pharmacy license, an asserted 503A status, a test claim, or a program’s marketing language as proof of equivalence, FDA approval, safety, or nationwide availability. Ask the clinician and dispensing source about the specific prescription and product instead.
Five safeguards before paying for an injectable GLP-1 offer
Confirm the product category and price terms
Ask whether the quoted product is an FDA-approved finished product or a compounded preparation. Obtain the amount due now, billing interval, term, included services, and renewal or cancellation conditions in writing. Do not convert a prepaid rate into a claim about a monthly bill.
Use a licensed prescriber and verify the pharmacy
FDA advises patients to obtain a prescription from their doctor and fill it at a state-licensed pharmacy. A screening does not guarantee that a clinician will prescribe a product. Verify the pharmacy identity rather than relying on an unfamiliar label or a platform claim.[3]
Read the label and ask about vial measurements
FDA has received reports of dosing errors with compounded injectable semaglutide, including incorrect measurement and administration. Discuss the intended measurement and administration instructions with the clinician or compounder before use; do not rely on generic online dosing advice.[3]
Check storage and single-use supplies
FDA says not to use an injectable GLP-1 that arrives warm or with insufficient refrigeration. For multi-dose sterile vials, FDA recommends discarding the vial within 28 days after first use and using a new sterile needle and syringe for each dose. Follow up with the dispensing source if the label or instructions are unclear.[3]
Avoid salt-form and online-sale shortcuts
FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs, lacks information that they have the same chemical and pharmacologic properties, and is not aware of a lawful basis for their use in compounding. FDA also flags deep discounts, absent licensed screening or prescription, damaged packages, and questionable pharmacy identities as telehealth warning signs. Discuss adverse events or quality problems with a clinician and report them to FDA MedWatch.[3]
Cost is not clinical eligibility
NIDDK explains that clinicians may prescribe weight-management medication for an adult with a body mass index (BMI) of 30 or greater, or 27 or greater with weight-related health problems. That framework is general context, not an individual eligibility determination. NIDDK also notes that prescription medication does not replace healthy eating and physical activity, and that these medicines work best when combined with a lifestyle program. Wegovy is listed there as once-weekly semaglutide for qualifying weight management; that discussion does not validate a compounded preparation.[4]
Commercial disclosure: Luma Health sells compounded semaglutide and has a commercial interest in readers choosing it.
Read the current terms,
then compare the actual amount due.
Review Luma’s published plan details directly. Eligibility, prescribing, and product choice remain with a licensed clinician.
View Current Luma Pricing →Learn about compounded semaglutideFrequently asked questions
There is no single universal amount. Luma’s published month-to-month price is $120 per month. Its 3-month and 6-month plans are $240 and $470 paid in full if prescribed, which are shown as $80 and about $78 monthly equivalents. Verify any program’s exact current terms directly.[1]
Include the amount due today, the billing interval, medication, consultation or membership charges, shipping, supplies or labs when applicable, prepayment, renewal, and cancellation terms. Compare the same product category and payment period rather than a headline rate alone.
No. Wegovy is an FDA-approved finished drug product. Compounded semaglutide is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.[3]
References
- Luma Health. Transparent Pricing. Accessed September 17, 2026.
- U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Content current April 1, 2026; accessed September 17, 2026.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current September 1, 2026; accessed September 17, 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity. Accessed September 17, 2026.
- Henry Meds. Programs: monthly and prepaid options. Page dated December 3, 2025; accessed September 17, 2026.
- Henry Meds. Online Weight Management: conditional prepaid offer. Accessed September 17, 2026.
- NovoCare. Wegovy Cost, Coverage, and Savings: product-specific offers and restrictions. Accessed September 17, 2026.